US · RGEN
Repligen Corporation
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Waltham, MA 02453
- Website
- repligen.com
Price · as of 2025-12-31
$117.20
Market cap 7.25B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $95.60 | -18.43% |
| Intrinsic Value(DCF) | $51.56 | -56.01% |
| Graham-Dodd Method(GD) | $21.98 | -81.24% |
| Graham Formula(GF) | $20.71 | -82.33% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $3.66 | $125.34 | $1.56 | $2.14 | $0.00 |
| 2012 | $6.77 | $1,270.96 | $476.73 | $4.98 | $59.88 |
| 2013 | $14.12 | $35.78 | $363.41 | $5.79 | $8.70 |
| 2014 | $31.31 | $49.11 | $90.77 | $4.26 | $0.41 |
| 2015 | $27.37 | $46.86 | $51.65 | $4.72 | $10.85 |
| 2016 | $32.24 | $53.48 | $41.90 | $4.99 | $11.21 |
| 2017 | $37.27 | $51.06 | $33.13 | $10.62 | $31.00 |
| 2018 | $56.73 | $63.78 | $110.30 | $8.50 | $16.67 |
| 2019 | $94.47 | $77.30 | $169.74 | $14.45 | $20.21 |
| 2020 | $194.70 | $116.97 | $89.73 | $23.03 | $48.10 |
| 2021 | $167.02 | $126.55 | $662.83 | $27.83 | $204.09 |
| 2022 | $166.27 | $118.89 | $208.16 | $35.79 | $90.12 |
| 2023 | $195.47 | $117.91 | $9.02 | $20.74 | $0.00 |
| 2024 | $155.70 | $95.62 | $5.73 | $14.55 | $0.00 |
| 2025 | $124.97 | $95.60 | $4.90 | $21.98 | $20.71 |
AI valuation
Our deep-learning model estimates Repligen Corporation's (RGEN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $95.60
- Current price
- $117.20
- AI upside
- -18.43%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$51.56
-56.01% upside
Graham-Dodd
$21.98
-81.24% upside
Graham Formula
$20.71
-82.33% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RGEN | Repligen Corporation | $117.20 | 7.25B | -18% | -56% | -81% | -82% | 143.73 | 3.34 | 9.52 | 42.30 | — | 11.60 | 47.09% | 8.07% | 6.62% | 2.40% | 2.38% | 1.69% | 0.33 | 2.57 | 8.37 | 6.82 | 0.75 | -28696.00% | 1636.00% | -3410.00% | 1.34% | 0.86 | 4.78% | 0.00% | 0.00% | 0.00% | 116.65 | 74.02 | 9.41 | 5.94 |
| ATR | AptarGroup, Inc. | $143.71 | 9.43B | -31% | -59% | -82% | -45% | 23.88 | 3.52 | 2.48 | 12.63 | 366.80 | 7.03 | 29.58% | 13.53% | 10.40% | 15.28% | 11.48% | 8.11% | 0.57 | 9.69 | 1.62 | 1.04 | 1.36 | 651.00% | 542.00% | -1422.00% | 3.19% | 0.49 | 8.43% | 1.29% | 30.80% | 5.18% | 20.55 | 35.05 | 2.78 | 4.13 |
| AVTR | Avantor, Inc. | $9.05 | 6.17B | +191% | -61% | — | — | -11.27 | 1.07 | 0.91 | 68.88 | — | -2.28 | 32.65% | -3.76% | -8.09% | -9.20% | -2.61% | -4.44% | 0.71 | -1.45 | 1.78 | 1.04 | 25.82 | -17500.00% | -341.00% | -2847.00% | 8.29% | 0.45 | 5.24% | 0.00% | 0.00% | 4.92% | -38.81 | 19.30 | 1.46 | 1.37 |
| BAX | Baxter International Inc. | $20.37 | 10.48B | +17% | -61% | — | — | -10.55 | 1.65 | 0.90 | 23.68 | -27.93 | -3.19 | 30.05% | -2.74% | -8.51% | -14.62% | -1.88% | -4.18% | 1.63 | -1.06 | 2.31 | 1.31 | 10.49 | 3780.00% | 572.00% | -4222.00% | 3.20% | 0.28 | 1.97% | 3.45% | -36.40% | 39.56% | -58.89 | 56.15 | 1.61 | 2.13 |
| BIO | Bio-Rad Laboratories, Inc… | $278.44 | 7.52B | +7% | -54% | +41% | -13% | 10.03 | 1.02 | 2.95 | 15.99 | — | 1.14 | 52.01% | 10.47% | 29.42% | 10.84% | 3.01% | 7.62% | 0.21 | 5.52 | 5.62 | 3.90 | 2.10 | -14264.00% | 65.00% | 4072.00% | 4.91% | 1.03 | 5.46% | 0.00% | 0.00% | 3.88% | 28.14 | 20.32 | 2.95 | 3.15 |
| CRL | Charles River Laboratorie… | $178.49 | 8.78B | -31% | -60% | — | — | -62.27 | 2.80 | 2.20 | 12.85 | — | 146.61 | 30.52% | 12.65% | -3.59% | -4.29% | 8.46% | -1.94% | 0.97 | 4.74 | 1.29 | 0.82 | 3.13 | -155500.00% | -85.00% | 337.00% | 5.86% | 0.66 | 8.64% | 0.00% | 0.00% | 4.07% | 23.05 | 22.57 | 2.91 | 2.48 |
| DVA | DaVita Inc. | $156.30 | 10.45B | -3% | -61% | — | -21% | 12.29 | -20.36 | 0.97 | 10.42 | — | -1.57 | 27.00% | 14.74% | 5.47% | -407.09% | 12.61% | 6.21% | -23.12 | 3.66 | 1.29 | 1.19 | 5.41 | -1137.00% | 646.00% | -1063.00% | 9.89% | 0.60 | 10.50% | 0.00% | 0.00% | 13.52% | 13.69 | 21.00 | 2.02 | 1.68 |
| GMED | Globus Medical, Inc. | $95.46 | 12.89B | +11% | +76% | -55% | 0% | 23.57 | 2.77 | 4.31 | 16.77 | 5.58 | 5.30 | 67.41% | 16.33% | 18.30% | 12.29% | 10.63% | 10.19% | 0.03 | — | 4.26 | 2.48 | -0.56 | 42267.00% | 1665.00% | 4530.00% | 4.64% | 1.51 | 14.79% | 0.00% | 0.00% | 3.63% | 25.51 | 20.79 | 4.16 | 12.01 |
| MASI | Masimo Corporation | $175.35 | 9.42B | — | -60% | — | -71% | -62.06 | 13.04 | 6.16 | 31.37 | — | 16.55 | 61.90% | 20.30% | -9.92% | — | — | — | 0.72 | — | 2.49 | 1.40 | 1.17 | — | — | — | 2.10% | 0.58 | — | 0.00% | 0.00% | 3.87% | 31.51 | 49.38 | 6.40 | 8.77 |
| STVN | Stevanato Group S.p.A. | $15.52 | 4.24B | +118% | -45% | -52% | -68% | 31.27 | 3.57 | 4.54 | 21.56 | — | 3.80 | 27.38% | 14.60% | 10.67% | 12.64% | 7.41% | 7.29% | 0.31 | 23.48 | 1.84 | 1.32 | 1.33 | -2182.00% | 172.00% | -5314.00% | -3.15% | 0.33 | -9.88% | 0.29% | 9.00% | 0.29% | 33.16 | -33.86 | 4.84 | 4.68 |
About Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
- CEO
- Olivier Loeillot
- Employees
- 1.78K
- Beta
- 1.13
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($51.56 ÷ $117.20) − 1 = -56.01% (DCF, example).